30 Years of Wnt Signalling: Special issue of the EMBO Journal celebrates 30 years of Wnt research

May 2012
Biomedical Market Newsletter;5/25/2012, Vol. 21, p1
The article presents information on the publication of a research related to Wnt signalling, a protein signalling pathway by the periodical.


Related Articles

  • Development of immunodetection system for botulinum neurotoxin type B using synthetic gene based recombinant protein. Jain, Swati; Ponmariappan, S.; Kumar, Om // Indian Journal of Medical Research;Jul2011, Vol. 134 Issue 1, p33 

    Background & objectives: Botulinum neurotoxins (A-G) are among most poisonous substances in the world, produced by obligate anaerobic bacteria Clostridum botulinum. Among the seven serotypes A, B, E and F are of human importance. In India, the prevalence of C. botulinum as well as botulism...

  • Lymphocyte responses: How RAG2 cycles. Minton, Kirsty // Nature Reviews Immunology;Aug2005, Vol. 5 Issue 8, p591 

    Discusses research being done on the ubiquitylation of recombination-activating gene 2 protein. Reference to a study by H. Jiang and colleagues published in a 2005 issue of "Molecular Cell" journal; Control of the generation of lymphocyte-specific antigen receptors; In vitro system used by the...

  • Recombinant proteins facility opens in Victoria. Dean, Tim // Australian Life Scientist;12/7/2009, p1 

    $11.2 million Victorian Recombinant Proteins Feeder Facility opens at Monash University.

  • Over Production of Human Recombinant Interferon α-2b: Scaling up Process. Susilo, Raphael Aswin; Sumirtapura, Yeyet C.; Rachmawati, Heni; Darijanto, Sasanti T.; Retnoningrum, Debbie S.; Kardono, Leonardus B. S. // Journal of Applied Sciences;8/ 1/2012, Vol. 12 Issue 15, p1613 

    This research aimed to exercise a large scale (bioreactor) process based on a laboratory experiment and to get control of process parameters on a large scale (bioreactor) to prepare an protein interferon α-2b. The study was initiated by a laboratory-scale protein interferon α-2b...

  • Recombinant Antibodies in Cancer Therapy. Nayeem, M. S.; Khan, Rizwan H. // Current Protein & Peptide Science;Apr2006, Vol. 7 Issue 2, p165 

    The application of recombinant immunotoxin and radioimmunoconjugate in Cancer therapy has revived the "magic bullet" concept predicted a century ago. Many of the recombinant antibodies have received FDA approval for various indication of cancer in recent years and numerous others are in clinical...

  • Impact of ‘LH activity’ supplementation on serum progesterone levels during controlled ovarian stimulation: a systematic review. Hugues, J.N. // Human Reproduction;Jan2012, Vol. 27 Issue 1, p232 

    BACKGROUND The influence of LH on serum progesterone rise during gonadotrophin stimulation is a matter of debate. The purpose of this analysis was to assess the impact of supplementation with ‘LH activity’ products on serum progesterone changes before hCG administration in GnRH...

  • Agents Targeting Apoptosis Show Promise in Early Trials. Tuma, Rabiya S. // JNCI: Journal of the National Cancer Institute;2/4/2009, Vol. 101 Issue 3, p138 

    The article reports that researchers are developing agents that directly target apoptosis signaling pathways to stop cancer cells growth. It notes that the first agent developed was the small-molecule inhibitor YM155 which can be safely administered and appears to have activity in patients with...

  • Selecting and screening recombinant antibody libraries. Hoogenboom, Hennie R. // Nature Biotechnology;Sep2005, Vol. 23 Issue 9, p1105 

    During the past decade several display methods and other library screening techniques have been developed for isolating monoclonal antibodies (mAbs) from large collections of recombinant antibody fragments. These technologies are now widely exploited to build human antibodies with high affinity...

  • Novel Thrombopoietic Agents. Stasi, Roberto; Evangelista, Maria L; Amadori, Sergio // Drugs;2008, Vol. 68 Issue 7, p901 

    The underlying problem in idiopathic thrombocytopenic purpura (ITP) has traditionally been recognized as accelerated platelet destruction. However, recent studies have provided evidence that the pathophysiology of ITP is more complex, and impaired platelet production has emerged as one of the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics